Written question asked by Tanmanjeet Singh Dhesi (Labour) on Wednesday, 1 February 2023, in the House of Commons. It was due for an answer on Friday, 3 February 2023. It was answered by Helen Whately (Conservative) on Tuesday, 7 February 2023 on behalf of the Department of Health and Social Care.
Breast Cancer: Chemotherapy
- Question
-
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 January 2023 to Question 119098 on Breast Cancer: Chemotherapy, whether appropriate data has been collected to reduce uncertainties in the evidence base for recommended technologies for tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer.
- Answer
-
Following a review of its diagnostics guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer [DG34], the National Institute for Health and Care Excellence (NICE) has confirmed that an update of its guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer [DG34] is in the very early stages of development.
Further information will be made available on NICE’s website as development of the updated guidance progresses.
Secondary information
- Type
- Written question
- Reference
- 137922
- Session
- 2022-23
- Related items
- Grouped for answer
- Yes
- Subjects
- Breast cancer Genetics Screening Chemotherapy
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-02-07 17:12:43 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/137922
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/137922
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/137922